GGHC
ARQT icon

Gilder Gagnon Howe & Co’s Arcutis Biotherapeutics ARQT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101M Sell
4,304,010
-149,846
-3% -$3.82M 1.22% 22
2025
Q4 		$129M Buy
4,453,856
+24,748
+0.6% +$634K 1.37% 18
2025
Q3 		$83.5M Buy
4,429,108
+273,345
+7% +$4.31M 0.85% 36
2025
Q2 		$58.3M Buy
4,155,763
+59,712
+1% +$837K 0.62% 50
2025
Q1 		$64.1M Buy
4,096,051
+193,060
+5% +$2.72M 0.84% 39
2024
Q4 		$54.4M Buy
3,902,991
+349,153
+10% +$3.83M 0.59% 49
2024
Q3 		$33.1M Sell
3,553,838
-62,694
-2% -$619K 0.4% 63
2024
Q2 		$33.6M Sell
3,616,532
-618,419
-15% -$5.59M 0.42% 64
2024
Q1 		$42M Buy
+4,234,951
New +$31.6M 0.52% 51

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return